Revelation Biosciences (REVB) Consolidated Net Income (2021 - 2026)

Revelation Biosciences (REVB) has reported Consolidated Net Income for 5 consecutive years, with -$2.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Consolidated Net Income fell 21.23% year-over-year to -$2.7 million; the TTM figure through Dec 2025 stood at -$9.2 million (down 7.87% YoY), while the FY2025 annual figure was -$26.7 million, down 215.48% from the prior year.
• Consolidated Net Income declined to -$2.7 million in Q4 2025 per REVB's latest filing, from -$1.9 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$1.2 million in Q3 2022 and bottomed at -$12.8 million in Q4 2023.
• Historically, Consolidated Net Income has averaged -$3.0 million across 5 years, with a median of -$2.3 million in 2021.
• Annual changes were most pronounced in 2023 — Consolidated Net Income tumbled 705.75% — and 2024, when it soared 82.6%.
• Revelation Biosciences' Consolidated Net Income stood at -$4.2 million in 2021, then surged by 62.22% to -$1.6 million in 2022, then sank by 705.75% to -$12.8 million in 2023, then jumped by 82.6% to -$2.2 million in 2024, then retreated by 21.23% to -$2.7 million in 2025.
• Business Quant data shows REVB's Consolidated Net Income at -$2.7 million in Q4 2025, -$1.9 million in Q3 2025, and -$2.5 million in Q2 2025.